Clinical trials: Oxycodone
Pain
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.
- Trial name
- NCT01648699
- Testing
- Osmotic Release Oral System (OROS) hydromorphone
- Volunteers
- 20 people
- Sponsor
- Janssen Pharmaceutica
Moderate to Severe Chronic Pain
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.
- Trial name
- NCT03802227
- Testing
- NKTR-181, Oxycodone IR
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nektar Therapeutics
Opioid-Related Disorders, Opiate Addiction
Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
The purpose of this study is to evaluate the effect on pain intensity (PI) of structured discontinuation of long-term opioid analgesic therapy compared to continuation of opioid therapy in Suboptimal and Optimal Responders to…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02741076
- Testing
- Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
- Where
- 61 sites in United States
- Volunteers
- 44 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Opioid Users
Abuse Potential Study of PF-00345439
This study will determine the relative abuse potential of intact and chewed PF-00345439 (Oxycodone Extended-Release Capsules) compared to crushed oxycodone HCL immediate release (IR) tablets and placebo administered orally to…
- Trial name
- NCT01986283
- Testing
- Capsule, PF-00345439, oxycodone
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Low Back Pain
Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment
The purpose of this study is to evaluate the efficacy of the study drug (Targin®) after 8 weeks of treatment in patients with moderate to severe low back pain who are uncontrolled* by NSAIDs.
- Trial name
- NCT03768466
- Testing
- Brand Name: Targin®
- Where
- 2 sites in South Korea
- Volunteers
- 123 people
- Sponsor
- Mundipharma Korea Ltd
Cancer
A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A multicenter, phase IV, interventional study to assess the efficacy and safety of Targin (Oxycodone/Naloxone) Korean patients with CIPN (Chemotherapy-Induced Peripheral Neuropathy) who need opioid combination treatment with…
- Trial name
- NCT01675531
- Testing
- Targin
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Mundipharma Korea Ltd
Osteoarthritis, Knee, Pain
Tapentadol (CG5503)
The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to…
- Trial name
- NCT00421928
- Testing
- oxycodone, tapentadol (CG5503)
- Volunteers
- 1,030 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions
To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, Inc., Lot No.
- Trial name
- NCT00864526
- Testing
- Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Low Back Pain
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
The primary objective is to assess the efficacy of oxycodone/naloxone (OXN) for the management of opioid-induced constipation (OIC) compared to oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low…
- Trial name
- NCT01427270
- Testing
- Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release
- Where
- 194 sites in United States, Czechia and 2 more
- Volunteers
- 455 people
- Sponsor
- Purdue Pharma LP
Interstitial Cystitis, Painful Bladder Syndrome
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects suffering from severe pain due to Bladder Pain Syndrome.
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome, Pain
- Trial name
- NCT01197261
- Testing
- Oxycodone naloxone prolonged release tablets
- Where
- 5 sites in Czechia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Chronic Pain
OTR Tablet 40 mg Fed-state Bioequivalence Study
An open-label, single dose, randomized, cross-over study to confirm the bioequivalence (BE) of OTR tablet 40 mg and OXYCONTIN tablet 40 mg in a fed state in Chinese subjects with chronic pain.
- Trial name
- NCT03398330
- Testing
- Oxycodone Tamper Resistant, OxyContin®
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain, Cancer
Clinical Study of KW-2246 in Patients With Cancer Pain
This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.
- Trial name
- NCT00355628
- Testing
- KW-2246 (fentanyl citrate)
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Pain
OTR Tablet 10 mg Fasted-state Bioequivalence Study
This is an open-label, single Dose, randomised, cross-over study to confirm the bioequivalence (BE) of OTR tablet 10 mg and OXYCONTIN tablet 10 mg in a fasted state in Chinese subjects with chronic pain
- Trial name
- NCT03403504
- Testing
- Oxycodone Tamper Resistant, OXYCONTIN®
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Healthy Volunteers
Single-Dose PK Study of an Oxycodone/Acetaminophen Solution in Healthy Subjects
A single-dose study evaluating the oral PK of an oxycodone/apap solution in healthy subjects under fasted conditions
- Trial name
- NCT02966860
- Testing
- Oral solution OC/APAP
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Pain
A Study of TRV130 for the Treatment of Pain After Abdominoplasty
The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with placebo in patients with acute postoperative pain following abdominoplasty.
- Trial name
- NCT02335294
- Testing
- TRV130, Morphine
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Trevena Inc.
Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant…
- Trial name
- NCT01192295
- Testing
- Oxycodone HCl controlled-release tablets
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 155 people
- Sponsor
- Purdue Pharma LP
Pain
OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study
A Single Dose PK Study of OxyNorm® immediate-release capsules 5, 10, and 20mg, and a multiple-dose PK Study of OxyNorm® immediate-release capsules 10mg in Chinese patients with pain.It will be a single center, open label…
- Trial name
- NCT01643772
- Testing
- Oxycodone hydrochloride
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Back Pain
The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.
The objective of this study is to assess the safety of the buprenorphine transdermal system (5, 10, and 20) in comparison to placebo transdermal system and immediate release oxycodone/ acetaminophen in subjects with chronic back…
- Trial name
- BP96-0604 (NCT00315445)
- Testing
- Buprenorphine transdermal patch, OXY/APAP
- Where
- 12 sites in United States
- Volunteers
- 134 people
- Sponsor
- Purdue Pharma LP
Postoperative Pain
Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients
This is a randomized, double-blind, multicenter, fixed dose factorial study of Q8003 12 mg/8 mg and Q8003 6 mg/4 mg versus its individual morphine sulfate and oxycodone hydrochloride components for the management of acute…
- Trial name
- NCT00831051
- Testing
- Q8003, Morphine sulfate, Oxycodone HCl
- Where
- 6 sites in United States
- Volunteers
- 197 people
- Sponsor
- QRxPharma Inc.
Human Abuse Potential
Assessment of Abuse Potential of Cebranopadol in Humans
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
- Trial name
- NCT05256108
- Testing
- Oxycodone 40 mg, Tramadol 600 mg, Cebranopadol 600 µg
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.